Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.

Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.

One first-in-human study and two deals in a single day sees companies blaze the ADC trail.